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Abstract
Despite significant advancements in osteosarcoma research, the overall survival of canine and human osteosarcoma
patients has remained essentially static over the past 2 decades. Post-operative limb-spare infection has been associated
with improved survival in both species, yet a mechanism for improved survival has not been clearly established. Given that
the majority of canine osteosarcoma patients experiencing post-operative infections were treated with fluoroquinolone
antibiotics, we hypothesized that fluoroquinolone antibiotics might directly inhibit the survival and proliferation of canine
osteosarcoma cells. Ciprofloxacin or enrofloxacin were found to inhibit p21WAF1 expression resulting in decreased
proliferation and increased S-G2/M accumulation. Furthermore, fluoroquinolone exposure induced apoptosis of canine
osteosarcoma cells as demonstrated by cleavage of caspase-3 and PARP, and activation of caspase-3/7. These results
support further studies examining the potential impact of quinolones on survival and proliferation of osteosarcoma.
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Introduction
Osteosarcoma (OSA) represents the most common primary
bone tumor in pet dogs. Surgical amputation of appendicular
OSA serves to remove the primary tumor and alleviate tumor-
associated pain but, unfortunately, the vast majority of dogs
harbor occult metastasis at the time of diagnosis [1,2]. As an
alternative to amputation, limb-salvage procedures can provide
adequate local control and yield median survival times similar to
those reported in dogs undergoing amputation. While post-
operative limb-spare infections are quite common in the dog,
multiple studies have found such infections to be associated with
improved survival when compared with similarly treated dogs
without infection [3–5]. One such study reported that 24 out of 32
dogs experiencing post-operative allograft infections were treated
with fluoroquinolone antibiotics [3], a class of drugs known to
have independent activity against several tissue and cancer cell
lines in vitro and in vivo [6–8]. Fluoroquinolones (FQs), such as
ciprofloxacin (CPFX) and enrofloxacin (ENFX), target topoisom-
erase enzymes and in this way share a similar mechanism to
traditional anti-neoplastic agents such as doxorubicin, irinotecan,
and etoposide [6,7,9]. Some FQs also have the ability to reverse
multidrug resistance-associated protein mediated drug resistance
[10], promote microRNA processing [11], induce immunomod-
ulatory effects [12], and are cytotoxic to vascular endothelial cells
[13]; indicating that they may possess both direct and indirect anti-
tumor activity when used in combination with traditional
chemotherapy.
Based upon these previous clinical and in vitro studies, we
questioned whether CPFX or ENFX might have direct effects on
canine osteosarcoma cells. We hypothesized that these specific
quinolones could directly inhibit the growth and/or survival of
canine OSA cells in vitro. To test this hypothesis, we exposed
canine OSA cell lines to CPFX or ENFX and performed in vitro
measures of proliferation and survival. Furthermore, we examined
CPFX and ENFX-induced changes in expression of proteins
associated with cell cycle progression and apoptosis in canine OSA
cells.
Results
Ciprofloxacin or enrofloxacin decreases total viable cell
number of canine OSA cells
We investigated the effect of CPFX or ENFX on three different
canine OSA cell lines. A significant decrease in the number of live
tumor cells was observed when OSA cells were exposed to
concentrations exceeding 1 mg/ml of CPFX in Abrams and D17
and 5 mg/ml in Moresco cells. Concentrations exceeding 5 mg/ml
of ENFX in Abrams and D17, and 10 mg/ml in Moresco cells
(Figure 1A; p,0.05) were required to inhibit the number of live
cells measured at day 4. CPFX or ENFX also inhibited colony
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formation in all three canine OSA cell lines in a concentration
dependent manner (Figure 1B).
Ciprofloxacin or enrofloxacin induces S-G2/M arrest
Based on the similarity in sensitivity between canine OSA cell
lines, we chose to focus mechanistic studies on Abrams cells. The
Abrams cell line seemed ideal based on previously published
positive characteristics of this cell line including in vivo growth and
the ability to form pulmonary metastases in nude mice [14]. In
order to explore the mechanism of FQ induced inhibition of OSA
cells, we performed cell cycle analyses. CPFX and ENFX
treatment of Abrams cells resulted in S-G2/M phase cell cycle
accumulation after exposure for 4 and 5 days at concentrations at
or above 20 ug/ml (Table 1). In addition, CPFX or ENFX both
increased the number of canine osteosarcoma cells in sub G1
(Figure 2).
Altered expression of cdc2 and phosphorylated cdc25C
in ciprofloxacin or enrofloxacin treated canine Abrams
OSA cells
To further examine the mechanism behind S-G2/M phase cell
cycle accumulation we examined the effects of FQ’s on expression
of several checkpoint proteins by western blot analysis. Treatment
with CPFX at 20 or 40 mg/ml resulted in reduced protein
expression of cdc2 (34 kDa) at five days, whereas reduced protein
expression at 4 days was only apparent at the 40 mg/ml
concentration (Figure 3). Consistent with results of the cell cycle
analysis, while ENFX appeared less potent than CPFX, it was still
effective at reducing the cdc2 expression in canine OSA cells; most
notable at a concentration of 40 mg/ml on day 5 (Figure 3). In
contrast, ENFX or CPFX resulted in similar increases in
expression of phospho-cdc25C in canine OSA cells after 4 or 5
days of exposure.
Ciprofloxacin and enrofloxacin activate caspase- 3 and 7
Because OSA cell exposure to FQ’s resulted in an increased sub
G1 fraction on cell cycle analysis, we wanted to examine whether
FQ’s were specifically capable of inducing apoptosis. We found
that Caspase-3/7 activity increased significantly (p=0.005, 0.001,
0.008, 0.002) in canine Abrams OSA cells after incubation either
with 20 or 40 mg/ml of CPFX or ENFX (Figure 4A). CPFX
induced activation of caspases was dose-dependent (p=0.001),
whereas no significant difference was detected between 40 mg/ml
of ENFX and the 20 mg/ml concentration (p=0.684).
Ciprofloxacin and enrofloxacin induce apoptosis
In order to further confirm that FQ’s were capable of inducing
apoptosis we performed Western blot analysis of PARP cleavage
Figure 1. The inhibitory effects of CPFX or ENFX on cell proliferation and colony formation in canine OSA cell lines (Abrams, D17,
Moresco). A. Inhibitory effect of CPFX and ENFX on cell proliferation evaluated by MTS assay. Data are presented as percent control. B. Influence of
canine OSA cells on the number of colony-forming cells treated with CPFX or ENFX was evaluated by clonogenic assay. Representative dishes by
colony-forming assay. Error bars represent S.D. Statistical significance was assessed using one-way ANOVA with post-hoc Tukey’s testing and
expressed as follows: * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0042960.g001
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which showed an increase in the cleaved fragment (89 kDa) in
Abrams cells treated with 20 or 40 mg/ml of CPFX at day 4,
whereas, both ENFX and CPFX increased PARP cleavage at day
5 (Figure 4B). Similarly, cleaved caspase-3 protein (cleaved to yield
17 and 19 kDa) was found to be increased by western blot analysis
when compared with untreated control cells at day 4 and 5.
Collectively, CPFX and ENFX were both found to induce
apoptotic cell death in canine OSA cells.
Ciprofloxacin and enrofloxacin reduce expression of p21
WAF1
Lastly, to further investigate the mechanism of FQ induced
changes in proliferation and survival we examined the effects of
FQ’s on p21 expression by Western blot. We found that expression
of p21 in canine Abrams OSA cells was markedly reduced after
48 hour exposure to either CPFX or ENFX (Figure 5).
Discussion
While adjuvant chemotherapy is known to improve the disease-
free interval and median survival time in canine and human
patients treated with adequate surgical control, survival has
remained relatively static for the past 20 years. However, post-
operative limb-spare infections have been associated with
improved survival in both species [3–5,15]. While some evidence
supports the notion that infection and/or a systemic anti-tumor
immune response can inhibit growth of canine OSA [16–20], one
clinical report noted that the majority of dogs experiencing post-
operative infection were treated with FQ antibiotics [3]. We
therefore questioned whether FQ’s might have direct effects on
canine OSA cells and set out to investigate any direct effects of
commonly used FQ’s on canine OSA cell lines in vitro.
ENFX is currently approved for use in several domestic species,
and is commonly prescribed in veterinary species with susceptible
infections. ENFX differs from CPFX by the presence of an ethyl
group, but pharmacokinetic elimination of ENFX is partially
accomplished by means of hepatic metabolism to CPFX [21,22].
Canine tissue levels of ENFX and CPFX vary significantly
between tissues and are dependent on the tissue type and the
administered dose [23,24]. In inflammatory tissues, the concen-
trations of ENFX and CPFX have been measured as high as
57 mg/g and 6 mg/g, respectively, after administration of a single
20 mg/kg dose of ENFX [24]. At this same administered dose,
mean tissue concentrations of ENFX and CPFX after a single dose
of ENFX reach 18.7 and 2.8 mg/g in the lung, respectively, [23]
which are within the range of concentrations used in this study.
However, it should be cautioned that these measured tissue
concentrations are based on tissue homogenates and may not be
truly representative of concentrations to which OSA cells would be
exposed in vivo. We evaluated the effect of ENFX or CPFX in
concentrations ranging from 1–40 mg/ml of the drug and found
dose and time-dependent effects (Figure 1). We have further
determined that similar levels of CPFX or ENFX can alter
expression of cell cycle proteins and induce apoptosis of canine
OSA cells.
Figure 2. CPFX and ENFX -induced S-G2/M arrest on in canine
OSA cells. The effect of CPFX (A) or ENFX (B) on cell cycle distribution
was investigated by flow cytometry in Abrams cells following 4 days or
5 days of treatment. Decreases in the proportions of cells in the G1
phase of the cell cycle and increases in the S and G2 phases were
observed. The actual percentage of gated cells are presented in
Table 1.
doi:10.1371/journal.pone.0042960.g002
Table 1. Percentage of gated cells in cell cycle analysis. CPFX
and ENFX treated with 20 or 40 ug/ml for 4 or 5 days on
Abram cell.
Drugs
Dosage
((mg/ml) ,g1 (%) G1 (%) S (%) G2/M (%)
Day 4 Control 0 2 82.5 5.0 8.6
CPFX 20 13.1 60.7 11.6 12.6
40 11.5 58.1 10.9 17.2
ENFX 20 9.5 70.9 8.4 9.7
40 6.6 69.2 10.2 12.7
Day 5 Control 0 1.7 83.8 5.0 8.0
CPFX 20 13.6 59.2 13.5 11.7
40 11.3 52.1 12.8 20.2
ENFX 20 13.1 62.8 10.7 11.7
40 14.0 62.3 10.4 11.6
doi:10.1371/journal.pone.0042960.t001
Antitumor Effects of FQs on Canine Osteosarcoma
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e42960
Several studies have demonstrated the cytotoxic and apoptosis-
inducing effects of FQ antibiotics on tendon cells, chondrocytes,
and a variety of human cancer cell lines [8,25–29]. However,
previous studies used a wide range of concentrations, and multiple
mechanisms of action have been implicated. The accumulation of
Abrams cells treated with ENFX or CPFX in the S and G2/M
phase of the cell cycle with concomitant induction of apoptotic cell
death is in agreement with previous reports of topoisomerase II
inhibition by CPFX resulting in S-G2/M arrest of prostate
carcinoma, transitional cell carcinoma, and colorectal carcinoma
cells [25,28,29]. While cell cycle analysis and apoptotic death were
not specifically evaluated in one previous study using human OSA
cells, our findings are consistent with previous reported results
demonstrating that CPFX is capable of inhibiting the growth of
human OSA cells at concentrations as low as 20 mg/ml [6].
Furthermore, we found that CPFX and ENFX decreased cdc2
expression concomitant with an increase in expression of phospho-
cdc25C and directly determined an S-G2/M cell cycle arrest by
flow cytometry (Figure 2, 3). Decreased expression of cyclin-
dependent kinase 1 (cdc2) has previously been reported in rat
tendon cells treated with 50 mg/ml of CPFX [30]. Regulation of
cdc2-B1 complex involves and activating phosphate by CDK-
activating enzyme and inhibitory phosphates at a pair of amino
acids in the roof of the active site by Wee 1. Dephosphorylation of
these sites by phosphatase cdc25C results in increased CDK
activity [31]. DNA damage is associated with many cellular events,
including activation of CHK1, which in turn phosphorylates and
inactivates cdc25C, allowing inactivation of the 2-B1 complex and
G2/M arrest [32].
CPFX and ENFX also led to decreased expression of the cyclin
dependent kinase inhibitor p21WAF1 (Figure 5). Previous studies
have also demonstrated p21WAF1 down-regulation in CPFX
treated cancer cells and indicated that the observed down-
regulation of p21WAF1 was likely due to the degradation of
p21WAF1 following ubiquitination by the 26S proteasome-mediat-
ed degradation pathway [28]; and that the observed degradation
was closely correlated with the time of induction of apoptotic cell
death [29]. Inhibition of p21WAF1 has previously been shown to
sensitize ME-180 OSA cells and MG63 human OSA cells during
TNF or anti-Fas-induced apoptosis [33,34]. This strongly suggests
the need to further evaluate the effect of FQs on mitochondria as
well as the proteasome-ubiquitination system in canine cancer cells
and raises the possibility that FQ’s could possibly enhance host
mediated immunologic cytotoxicity of OSA.
In addition to cell cycle perturbations, our experiments revealed
an in vitro apoptotic effect of CPFX or ENFX on canine OSA
cells, in a dose - and time -dependent manner. Caspase-3 is a key
member of the caspase family, which is the central component of
the apoptotic machinery during apoptotic cell death. Poly (ADP-
ribose) polymerase (PARP) is a common death substrate for
activated enzymes of caspase family and caspase-3 and caspase-7
demonstrated both cleave PARP [35]. As shown in Figure 4B,
Figure 3. G2 checkpoint kinases affected by CPFX and ENFX treatment. Western blot analysis of cdc2 (CDK1) and cdc25C in Abrams OSA
cells at day 4 and 5. Both CPFX and ENFX inhibit G2 checkpoint kinase cdc2 although CPFX showed more potent than ENFX. The level of phospho-
cdc25C was increased in both CPFX and ENFX treated canine Abrams OSA cells.
doi:10.1371/journal.pone.0042960.g003
Figure 4. Activation of apoptotic cell death induced by CPFX or ENFX. A. Caspase-3/7 activity was measured in relative fluorescence unit
with a commercial assay kit in canine Abrams OSA cells following incubation with CPFX (20 and 40 mg/ml) or ENFX (20 and 40 mg/ml) for 72 hours. **
Significantly (p,0.01) different from value for untreated control cells. B. Western blot analysis of PARP cleavage and cleaved caspase-3. Apoptosis is
indicated by the increase of cleaved-PARP and cleaved-caspase-3.
doi:10.1371/journal.pone.0042960.g004
Antitumor Effects of FQs on Canine Osteosarcoma
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activation of caspase-3 after ENFX or CPFX treatment of the
canine OSA cells was confirmed by western blot analysis and the
activation of caspase-3 was correlated with the proteolytic cleavage
of PARP. These results correspond with previous investigations in
human bladder cancer cells exposed to 100–300 mg/ml of CPFX
[28].
The experiments in this study were designed to determine
whether or not FQs were directly capable of inhibiting survival
and proliferation in canine OSA cells. Based on our findings, it is
possible that the use of FQ’s in clinical patients may have
contributed to the improved outcome of dogs with OSA.
However, much work is needed before such a conclusion can be
made. While our results support further study of FQs or possibly
other quinolones in the treatment of OSA, many questions
remain. Specifically of concern is that while reduction in p21 has
been previously shown to increase apoptosis in some cells, loss of
p21 expression can increase cellular proliferation in other cells and
may contribute to carcinogenesis and tumor progression [36].
Therefore, our results must be interpreted with caution until
further in vitro and in vivo studies can be performed.
Materials and Methods
Drugs
CPFX (catalogue #17850) and ENFX (catalogue#17850) were
purchased from Sigma and dissolved in 0.1N HCL (pH=1) at a
concentration of 25 mg/ml or 10 mg/ml respectively.
Cell cultures
Abrams and Moresco cell lines were kindly provided by Dr.
Douglas Thamm, Department of Clinical Sciences College of
Veterinary Medicine and Biomedical Sciences Colorado State
University. D-17 (CCL-183) cell was purchased from American
Type Culture Collection. Cell lines were maintained at 37uC in
DMEM medium (GibcoH) supplemented with 10% FBS, 1%
penicillin/streptomycin (GibcoH), 1% MEM non-essential amino
acids (cellgroH) and 1% MEM vitamins (GibcoH) in 5% humidified
CO2 chamber. All cell lines were determined to be free of
mycoplasma using commertial PCR detection kit (MycoScopeTM,
Genlantis, CA).
Cell proliferation assay
Canine OSA cells were plated in triplicate at a density of 800
cells for Abrams and 2000 cells for Moresco and D17 in 96 well
plates. Cells were cultured for at least 24 h prior to the
experiment. Culture medium was replaced with fresh medium
containing different concentrations of CPFX or ENFX at
concentrations between 0–40 mg/ml for 4 days. Cell number
was measured by incubation with the 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in-
ner salt (MTS) one –solution assay reagent (CellTiter 96*,
Promega) at 37uC for 1 h before reading absorbance on a
spectrophotometer (SpectraMax 190, Molecular Devices) at
490 nm. CPFX and ENFX were tested in the absence of cells
and determined not to interfere with tetrazolium salts. Indepen-
dent assays were repeated a minimum of three times.
Clonogenic assay
Cell survival was assessed by clonogenic assay as previously
described [37]. In brief, cells were plated onto 6-well plates (1000
cells per dish) allowed to adhere overnight, and treated afterward
with CPFX or ENFX at concentrations of 0, 1,5,10,20 and 40 mg/
ml and incubated for 8 days. On day 8, the colonies were stained
with crystal violet (in ethyl alcohol). Each experiment was repeated
at least five times.
Cell cycle Analysis
The effect of CPFX or ENFX on cell cycle distribution was
determined by flow cytometry following staining of the cells with
propidium iodide. Briefly, cells (26105 cells) were seeded and
allowed to attach overnight. The medium was replaced with media
without FBS and incubated for 30 h. Then, following 4 and 5 days
of treatment with CPFX or ENFX at concentrations of 0,
1,5,10,20 and 40 mg/ml, floating and attached cells were
harvested and centrifuged at 8946 g for 3 min. The samples
were washed with PBS and fixed in 70% ethanol. The cells were
then treated with 100 mg/ml RNase A and 50 mg/ml propidium
iodide for 30 min and analyzed using a FACScan flow cytometer
and Cell Quest software (Becton Dickinson).
Antibodies
Rabbit polyclonal anti-cdc2, mouse monoclonal anti-actin, and
anti-p21 were purchased form Santa Cruz Biotechnology. Rabbit
polyclonal anti-cleaved PARP, anti-cleaved caspase-3 and mouse
monoclonal anti-phospho cdc25C was obtained from Cell
Signaling .
Western blot Analysis
After treatment with CPFX or ENFX at concentrations of 0, 20
and 40 mg/ml on Abrams for 4 and 5 days, floating and attached
cells were collected and lysed. Lysed samples were heated at 95uC
for 10 min and cleared by centrifugation at 100006g for 20 min.
Lysate protiens were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto nitrocellulose membrane. The membrane was incubated with
Tris-buffered saline (PBS) containing Tween 20 (0.05%) and 3%
(w/v) non-fat dry milk (PBST for phospho cdc25C) and exposed to
the desired primary antibody at 4uC overnight. Following
treatment with appropriate secondary antibody, the immunore-
active bands were visualized using enhanced chemiluminescence
method.
Caspase-3/7 activity assay
Apoptosis was assessed by measuring caspase-3/7 activity. In
brief, 36105 Abrams cells were plated in 6-well plates in 2 ml of
high glucose DMEM medium with 10% fetal bovine serum and
incubated overnight at 37uC and 5% CO2. CPFX or ENFX (20 or
40 mg/ml) was added to the wells, and plates were incubated for
an additional 72 h. Caspase-3/7 activity was then measured with a
commercial assay performed in accordance with the manufactur-
er’s specifications. Fluorescence was quantified with a spectroflu-
orometer microplate reader (SPCTRA max Gemini, Molecular
Figure 5. Decreased expression of p21 by CPFX or ENFX.
Western blot analysis in Abrams OSA cells treated with CPFX or ENFX at
a dose of 20 mg/ml or 40 mg/ml at day 2. Abrams cells treated with
doxorubicin were used as a positive control.
doi:10.1371/journal.pone.0042960.g005
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Device) at an excitation wavelength of 354 nm and emission wave
length of 442 nm. Cells treated with doxorubicin (0.5 mM) were
used as the positive control, and untreated cells were used as the
negative control. Samples were analyzed in triplicate, and each
experiment was repeated 3 times.
Statistical analysis
The results shown are representative of experiments repeated a
minimum of three times. For MTS assay, the effects of CPFX and
ENFX concentrations were compared individually for each drug
and each cell line by one-way ANOVA and post-hoc Tukey’s
testing. For caspase 3/7 activity, one-way ANOVA and post-hoc
Tukey’s testing was applied to all groups. Differences were
considered significant with a p,0.05.
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